Lysophosphatidylcholine Dynamics in Atherosclerosis Mechanisms

Lysophosphatidylcholine (LPC) is a bioactive lipid generated during the oxidative modification of low-density lipoprotein and through phospholipase-mediated deacylation of membrane phosphatidylcholine. Within the arterial intima, LPC accumulates and exerts multifaceted effects: it disrupts endothelial barrier function, promotes expression of cell adhesion molecules, and triggers reactive oxygen species generation. In parallel, LPC drives monocyte recruitment and differentiation into lipid-laden foam cells, and it engages innate immune pathways such as Toll-like receptors and the NLRP3 inflammasome to amplify interleukin-1β signalling. The dynamic balance between LPC production and its reacylation by lysophosphatidylcholine acyltransferases governs membrane remodelling, plaque stability and the progression of chronic vascular inflammation. Understanding these interconnected mechanisms is critical for identifying novel biomarkers and therapeutic targets in the prevention and treatment of atherosclerotic cardiovascular disease.

Research from Nature Portfolio

Recent studies have elucidated the structural basis of LPC remodelling by LPCAT3, revealing a bifurcated reaction chamber that guides arachidonoyl-CoA and LPC substrates into adjacent tunnels converging at the catalytic centre. High-resolution cryo-EM and crystallography have defined key residues mediating acyl-chain selectivity and membrane integration. These insights establish a mechanistic framework for how LPCAT3 activity controls phospholipid composition, membrane fluidity and downstream inflammatory signalling in vascular cells.

Lysophosphatidylcholine Dynamics in Atherosclerosis Mechanisms publication trend

The graph below shows the total number of articles in lysophosphatidylcholine dynamics in atherosclerosis mechanisms across all publications each year (not limited to Nature Index journals).

Technical terms

Lysophosphatidylcholine (LPC): A lysophospholipid formed by removal of one fatty acyl chain from phosphatidylcholine, implicated in vascular inflammation and atherogenesis.

Foam cell: A lipid-engorged macrophage that accumulates cholesterol esters and contributes to the fatty streaks of early atherosclerotic lesions.

NLRP3 inflammasome: A cytosolic multiprotein complex that senses danger signals and activates caspase-1 to process interleukin-1β and interleukin-18.

Lysophosphatidylcholine acyltransferase (LPCAT): An enzyme that reacylates LPC to phosphatidylcholine, essential for membrane lipid remodelling and homeostasis.

Reactive oxygen species (ROS): Chemically reactive molecules derived from oxygen that function in cellular signalling but can induce oxidative damage when overproduced.

References

1. Inflammation and oxidative stress markers in type 2 diabetes patients with Advanced Carotid atherosclerosis. Cardiovascular Diabetology (2023).
2. The structural basis for the phospholipid remodeling by lysophosphatidylcholine acyltransferase 3. Nature Communications (2021).
3. An Updated Review of Pro- and Anti-Inflammatory Properties of Plasma Lysophosphatidylcholines in the Vascular System. International Journal of Molecular Sciences (2020).
4. Lysophosphatidylcholine induces oxidative stress in human endothelial cells via NOX5 activation – implications in atherosclerosis. Clinical Science (2021).
5. Lysophosphatidylcholine Induces NLRP3 Inflammasome-Mediated Foam Cell Formation and Pyroptosis in Human Monocytes and Endothelial Cells. Frontiers in Immunology (2020).